ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,111Medicare Part D Prescriptions Filled, Including Refills

Rank: 56 out of 1269

$1.06M Total Retail Price of All Prescriptions

Rank: 20 out of 1269

482 Patients Receiving at Least One Drug in Part D
93%Patients 65 Years and Older
81% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

2% of this provider’s 482 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

7% of this provider’s 482 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

3% of this provider’s 10,746 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

39% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$95 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
NEXIUM 643 637 1 41
ALENDRONATE SODIUM 481 468 2 28
LIDODERM 465 460 3 56
AMLODIPINE BESYLATE 410 408 4 2
METFORMIN HCL 391 358 5 9
PRAVASTATIN SODIUM 359 347 6 11
DIOVAN HCT 262 249 7 76
CELEBREX 252 252 8 95
MELOXICAM 233 225 9 68
OMEPRAZOLE 232 225 10 8
TAMSULOSIN HCL 224 220 11 31
RANITIDINE HCL 221 213 12 27
HYDROCHLOROTHIAZIDE 218 216 13 10
SIMVASTATIN 181 178 14 3
ZOLPIDEM TARTRATE 169 166 15 19
LEVOTHYROXINE SODIUM 169 161 15 4
METOPROLOL SUCCINATE 162 160 17 13
LISINOPRIL 155 150 18 1
CRESTOR 150 140 19 25
GLIMEPIRIDE 140 131 20 57
METOPROLOL TARTRATE 137 129 21 6
HYDROCODONE-ACETAMINOPHEN 131 123 S3 22 20
VERAPAMIL HCL 125 125 23 296
LOSARTAN POTASSIUM 124 116 24 15
ATORVASTATIN CALCIUM 123 122 25 7
DIOVAN 104 94 26 35
FUROSEMIDE 104 96 26 5
NAMENDA 100 100 28 38
GLYBURIDE-METFORMIN HCL 100 100 R 28 172
LOSARTAN-HYDROCHLOROTHIAZIDE 99 87 30 59
ATELVIA 97 97 31 247
VOLTAREN 91 90 32 162
GLIPIZIDE 81 81 33 37
LYRICA 80 80 34 92
GABAPENTIN 76 75 35 17
LIPITOR 76 76 35 91
PLAVIX 73 73 37 47
ATENOLOL 69 69 38 14
LOVASTATIN 67 67 39 30
AZITHROMYCIN 63 57 40 42
ACTOS 61 53 41 161
SINGULAIR 61 61 41 123
EVISTA 61 61 41 208
DEXILANT 60 59 44 200
GLYBURIDE 60 59 R 44 94
CLOPIDOGREL 59 59 46 32
PANTOPRAZOLE SODIUM 58 56 47 18
BONIVA 55 55 48 373
MEGESTROL ACETATE 52 52 R 49 236
LANSOPRAZOLE 50 50 50 120
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 28, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.